Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy - Results from ACRIN 6657/I-SPY TRIAL

Nola M. Hylton, Jeffrey D. Blume, Wanda K. Bernreuter, Etta D. Pisano, Mark A. Rosen, Elizabeth A. Morris, Paul T. Weatherall, Constance D. Lehman, Gillian M. Newstead, Sandra Polin, Helga S. Marques, Laura J. Esserman, Mitchell D. Schnall

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

Purpose: To compare magnetic resonance (MR) imaging findings and clinical assessment for prediction of pathologic response to neoadjuvant chemotherapy (NACT) in patients with stage II or III breast cancer. Materials and Methods: The HIPAA-compliant protocol and the informed consent process were approved by the American College of Radiology Institutional Review Board and local-site institutional review boards. Women with invasive breast cancer of 3 cm or greater undergoing NACT with an anthracycline-based regimen, with or without a taxane, were enrolled between May 2002 and March 2006. MR imaging was performed before NACT (first examination), after one cycle of anthracyline-based treatment (second examination), between the anthracycline-based regimen and taxane (third examination), and after all chemotherapy and prior to surgery (fourth examination). MR imaging assessment included measurements of tumor longest diameter and volume and peak signal enhancement ratio. Clinical size was also recorded at each time point. Change in clinical and MR imaging predictor variables were compared for the ability to predict pathologic complete response (pCR) and residual cancer burden (RCB). Univariate and multivariate random-effects logistic regression models were used to characterize the ability of tumor response measurements to predict pathologic outcome, with area under the receiver operating characteristic curve (AUC) used as a summary statistic. Results: Data in 216 women (age range, 26-68 years) with two or more imaging time points were analyzed. For prediction of both pCR and RCB, MR imaging size measurements were superior to clinical examination at all time points, with tumor volume change showing the greatest relative benefit at the second MR imaging examination. AUC differences between MR imaging volume and clinical size predictors at the early, mid-, and posttreatment time points, respectively, were 0.14, 0.09, and 0.02 for prediction of pCR and 0.09, 0.07, and 0.05 for prediction of RCB. In multivariate analysis, the AUC for predicting pCR at the second imaging examination increased from 0.70 for volume alone to 0.73 when all four predictor variables were used. Additional predictive value was gained with adjustments for age and race. Conclusion: MR imaging findings are a stronger predictor of pathologic response to NACT than clinical assessment, with the greatest advantage observed with the use of volumetric measurement of tumor response early in treatment.

Original languageEnglish (US)
Pages (from-to)663-672
Number of pages10
JournalRadiology
Volume263
Issue number3
DOIs
StatePublished - 2012

Fingerprint

Magnetic Resonance Imaging
Breast Neoplasms
Drug Therapy
Residual Neoplasm
Area Under Curve
Research Ethics Committees
Anthracyclines
Logistic Models
Health Insurance Portability and Accountability Act
Neoplasms
Tumor Burden
Informed Consent
Radiology
ROC Curve
Multivariate Analysis
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Hylton, N. M., Blume, J. D., Bernreuter, W. K., Pisano, E. D., Rosen, M. A., Morris, E. A., ... Schnall, M. D. (2012). Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy - Results from ACRIN 6657/I-SPY TRIAL. Radiology, 263(3), 663-672. https://doi.org/10.1148/radiol.12110748

Locally advanced breast cancer : MR imaging for prediction of response to neoadjuvant chemotherapy - Results from ACRIN 6657/I-SPY TRIAL. / Hylton, Nola M.; Blume, Jeffrey D.; Bernreuter, Wanda K.; Pisano, Etta D.; Rosen, Mark A.; Morris, Elizabeth A.; Weatherall, Paul T.; Lehman, Constance D.; Newstead, Gillian M.; Polin, Sandra; Marques, Helga S.; Esserman, Laura J.; Schnall, Mitchell D.

In: Radiology, Vol. 263, No. 3, 2012, p. 663-672.

Research output: Contribution to journalArticle

Hylton, NM, Blume, JD, Bernreuter, WK, Pisano, ED, Rosen, MA, Morris, EA, Weatherall, PT, Lehman, CD, Newstead, GM, Polin, S, Marques, HS, Esserman, LJ & Schnall, MD 2012, 'Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy - Results from ACRIN 6657/I-SPY TRIAL', Radiology, vol. 263, no. 3, pp. 663-672. https://doi.org/10.1148/radiol.12110748
Hylton, Nola M. ; Blume, Jeffrey D. ; Bernreuter, Wanda K. ; Pisano, Etta D. ; Rosen, Mark A. ; Morris, Elizabeth A. ; Weatherall, Paul T. ; Lehman, Constance D. ; Newstead, Gillian M. ; Polin, Sandra ; Marques, Helga S. ; Esserman, Laura J. ; Schnall, Mitchell D. / Locally advanced breast cancer : MR imaging for prediction of response to neoadjuvant chemotherapy - Results from ACRIN 6657/I-SPY TRIAL. In: Radiology. 2012 ; Vol. 263, No. 3. pp. 663-672.
@article{a0d4500d5b7249cfa5adff7d21c005f8,
title = "Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy - Results from ACRIN 6657/I-SPY TRIAL",
abstract = "Purpose: To compare magnetic resonance (MR) imaging findings and clinical assessment for prediction of pathologic response to neoadjuvant chemotherapy (NACT) in patients with stage II or III breast cancer. Materials and Methods: The HIPAA-compliant protocol and the informed consent process were approved by the American College of Radiology Institutional Review Board and local-site institutional review boards. Women with invasive breast cancer of 3 cm or greater undergoing NACT with an anthracycline-based regimen, with or without a taxane, were enrolled between May 2002 and March 2006. MR imaging was performed before NACT (first examination), after one cycle of anthracyline-based treatment (second examination), between the anthracycline-based regimen and taxane (third examination), and after all chemotherapy and prior to surgery (fourth examination). MR imaging assessment included measurements of tumor longest diameter and volume and peak signal enhancement ratio. Clinical size was also recorded at each time point. Change in clinical and MR imaging predictor variables were compared for the ability to predict pathologic complete response (pCR) and residual cancer burden (RCB). Univariate and multivariate random-effects logistic regression models were used to characterize the ability of tumor response measurements to predict pathologic outcome, with area under the receiver operating characteristic curve (AUC) used as a summary statistic. Results: Data in 216 women (age range, 26-68 years) with two or more imaging time points were analyzed. For prediction of both pCR and RCB, MR imaging size measurements were superior to clinical examination at all time points, with tumor volume change showing the greatest relative benefit at the second MR imaging examination. AUC differences between MR imaging volume and clinical size predictors at the early, mid-, and posttreatment time points, respectively, were 0.14, 0.09, and 0.02 for prediction of pCR and 0.09, 0.07, and 0.05 for prediction of RCB. In multivariate analysis, the AUC for predicting pCR at the second imaging examination increased from 0.70 for volume alone to 0.73 when all four predictor variables were used. Additional predictive value was gained with adjustments for age and race. Conclusion: MR imaging findings are a stronger predictor of pathologic response to NACT than clinical assessment, with the greatest advantage observed with the use of volumetric measurement of tumor response early in treatment.",
author = "Hylton, {Nola M.} and Blume, {Jeffrey D.} and Bernreuter, {Wanda K.} and Pisano, {Etta D.} and Rosen, {Mark A.} and Morris, {Elizabeth A.} and Weatherall, {Paul T.} and Lehman, {Constance D.} and Newstead, {Gillian M.} and Sandra Polin and Marques, {Helga S.} and Esserman, {Laura J.} and Schnall, {Mitchell D.}",
year = "2012",
doi = "10.1148/radiol.12110748",
language = "English (US)",
volume = "263",
pages = "663--672",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "3",

}

TY - JOUR

T1 - Locally advanced breast cancer

T2 - MR imaging for prediction of response to neoadjuvant chemotherapy - Results from ACRIN 6657/I-SPY TRIAL

AU - Hylton, Nola M.

AU - Blume, Jeffrey D.

AU - Bernreuter, Wanda K.

AU - Pisano, Etta D.

AU - Rosen, Mark A.

AU - Morris, Elizabeth A.

AU - Weatherall, Paul T.

AU - Lehman, Constance D.

AU - Newstead, Gillian M.

AU - Polin, Sandra

AU - Marques, Helga S.

AU - Esserman, Laura J.

AU - Schnall, Mitchell D.

PY - 2012

Y1 - 2012

N2 - Purpose: To compare magnetic resonance (MR) imaging findings and clinical assessment for prediction of pathologic response to neoadjuvant chemotherapy (NACT) in patients with stage II or III breast cancer. Materials and Methods: The HIPAA-compliant protocol and the informed consent process were approved by the American College of Radiology Institutional Review Board and local-site institutional review boards. Women with invasive breast cancer of 3 cm or greater undergoing NACT with an anthracycline-based regimen, with or without a taxane, were enrolled between May 2002 and March 2006. MR imaging was performed before NACT (first examination), after one cycle of anthracyline-based treatment (second examination), between the anthracycline-based regimen and taxane (third examination), and after all chemotherapy and prior to surgery (fourth examination). MR imaging assessment included measurements of tumor longest diameter and volume and peak signal enhancement ratio. Clinical size was also recorded at each time point. Change in clinical and MR imaging predictor variables were compared for the ability to predict pathologic complete response (pCR) and residual cancer burden (RCB). Univariate and multivariate random-effects logistic regression models were used to characterize the ability of tumor response measurements to predict pathologic outcome, with area under the receiver operating characteristic curve (AUC) used as a summary statistic. Results: Data in 216 women (age range, 26-68 years) with two or more imaging time points were analyzed. For prediction of both pCR and RCB, MR imaging size measurements were superior to clinical examination at all time points, with tumor volume change showing the greatest relative benefit at the second MR imaging examination. AUC differences between MR imaging volume and clinical size predictors at the early, mid-, and posttreatment time points, respectively, were 0.14, 0.09, and 0.02 for prediction of pCR and 0.09, 0.07, and 0.05 for prediction of RCB. In multivariate analysis, the AUC for predicting pCR at the second imaging examination increased from 0.70 for volume alone to 0.73 when all four predictor variables were used. Additional predictive value was gained with adjustments for age and race. Conclusion: MR imaging findings are a stronger predictor of pathologic response to NACT than clinical assessment, with the greatest advantage observed with the use of volumetric measurement of tumor response early in treatment.

AB - Purpose: To compare magnetic resonance (MR) imaging findings and clinical assessment for prediction of pathologic response to neoadjuvant chemotherapy (NACT) in patients with stage II or III breast cancer. Materials and Methods: The HIPAA-compliant protocol and the informed consent process were approved by the American College of Radiology Institutional Review Board and local-site institutional review boards. Women with invasive breast cancer of 3 cm or greater undergoing NACT with an anthracycline-based regimen, with or without a taxane, were enrolled between May 2002 and March 2006. MR imaging was performed before NACT (first examination), after one cycle of anthracyline-based treatment (second examination), between the anthracycline-based regimen and taxane (third examination), and after all chemotherapy and prior to surgery (fourth examination). MR imaging assessment included measurements of tumor longest diameter and volume and peak signal enhancement ratio. Clinical size was also recorded at each time point. Change in clinical and MR imaging predictor variables were compared for the ability to predict pathologic complete response (pCR) and residual cancer burden (RCB). Univariate and multivariate random-effects logistic regression models were used to characterize the ability of tumor response measurements to predict pathologic outcome, with area under the receiver operating characteristic curve (AUC) used as a summary statistic. Results: Data in 216 women (age range, 26-68 years) with two or more imaging time points were analyzed. For prediction of both pCR and RCB, MR imaging size measurements were superior to clinical examination at all time points, with tumor volume change showing the greatest relative benefit at the second MR imaging examination. AUC differences between MR imaging volume and clinical size predictors at the early, mid-, and posttreatment time points, respectively, were 0.14, 0.09, and 0.02 for prediction of pCR and 0.09, 0.07, and 0.05 for prediction of RCB. In multivariate analysis, the AUC for predicting pCR at the second imaging examination increased from 0.70 for volume alone to 0.73 when all four predictor variables were used. Additional predictive value was gained with adjustments for age and race. Conclusion: MR imaging findings are a stronger predictor of pathologic response to NACT than clinical assessment, with the greatest advantage observed with the use of volumetric measurement of tumor response early in treatment.

UR - http://www.scopus.com/inward/record.url?scp=84862501734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862501734&partnerID=8YFLogxK

U2 - 10.1148/radiol.12110748

DO - 10.1148/radiol.12110748

M3 - Article

C2 - 22623692

AN - SCOPUS:84862501734

VL - 263

SP - 663

EP - 672

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 3

ER -